Evotec (EVT.DE) traded down -0.28 % during a 24 hours period ending at 08:33 AM Central Europe on Tuesday 27th. One Evotec stock can currently be bought for about EUR 2.8 on popular exchanges. Current supply of Evotec stocks is 179 mn. Evotec has a current market capitalization of EUR 501.6 mn and approximately EUR 2.6 mn worth of Evotec was traded on exchanges in the last 24 hours. Since last month end, Evotec has traded -2.03 % down. Simple moving average of last 200 days is at EUR 4.44. The highest price of past 52 weeks was recorded at EUR 7.21 on 10/29/2025. 52 weeks low was at EUR 2.41 on 10/13/2026.

Summary of the latest news for Evotec

On 26 October 2026, the German regulator recorded two separate reports of net short positions in Evotec SE, with holders indicating holdings of roughly half a percent of the issued share capital in each case. In parallel, the company’s shares were among the least active performers in the TecDAX index that day, with a modest decline and a trading price near the lower end of the index’s range. No further corporate actions or earnings releases were disclosed for Evotec SE in the material covered.

Here is how related stocks have performed in the past 24 hours:

  • Procredit (PCZ.DE) traded up 0.58 % and now trades at EUR 8.74. Procredit has a market capitalisation of EUR 518.3 mn. Current price/earnings ratio for Procredit is 6.92.

  • Mensch Und Maschine Software (MUM.DE) traded down -0.15 % and now trades at EUR 33.95. Mensch Und Maschine Software has a market capitalisation of EUR 559.8 mn. Current price/earnings ratio for Mensch Und Maschine Software is 17.35.

  • Carbon (SGL.DE) traded down -1.53 % and now trades at EUR 4.82. Current market capitalisation for Carbon is EUR 584.5 mn. SGL Carbon SE has reported a modest improvement in its operating outlook for the year. Management highlighted a slight strengthening of revenue momentum driven by a combination of higher pricing and expanded order volumes across its key markets. The company also noted that its cost base has remained relatively stable, supported by ongoing efficiencies in production and supply‑chain management. In the same period, the firm’s guidance indicated that it expects the next quarter’s earnings to reflect a moderate uptick, following a trend of incremental gains seen in recent quarters.

  • Hypoport (HYQ.DE) traded down -2.81 % and now trades at EUR 81.35. Hypoport has a market capitalisation of EUR 552.1 mn. Current price/earnings ratio for Hypoport is 19.45. Hypoport SE reported that its earnings before interest and taxes rose in the third quarter of 2026 compared with the same period the previous year. The company highlighted growth in gross profit and operating income across its three main segments – Real Estate & Mortgage Platforms, Financing Platforms and Insurance Platforms – during the nine‑month period ending in October. Management noted that the overall improvement was driven by a mix of business models within these segments. The preliminary figures suggest a strengthening of profitability, and the company plans to release final results for the first nine months of 2026 on 9 November. In the market, the Hypoport share experienced a modest decline in the afternoon session, reflecting broader market movements within the SDAX.

About Evotec

Evotec SE is a pharmaceutical company specializing in drug discovery solutions in various therapeutic areas including neuroscience, diabetes, pain and inflammation, oncology, infectious diseases, respiratory, and fibrosis. The company serves pharmaceutical and biotechnology companies worldwide, striving to develop innovative therapies to address unmet medical needs.